FDA Wants Your Pain Points: New Guide for Patient-Centric Drug Tools
Published Date: 11/18/2025
Notice
Summary
The FDA just released new guidance to help drug makers and researchers better include patient experiences when creating or updating tools that measure how well treatments work. This means patients, caregivers, and industry folks can share real-world info to make drug development more patient-friendly. The guidance is effective now and aims to speed up smarter, more meaningful medical product decisions without extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Patients Can Submit Experience Data
You (patients, caregivers, researchers, and medical product developers) can collect and submit patient experience and caregiver information to the FDA to be used for medical product development and regulatory decision-making. The final guidance, announced November 18, 2025, explains how to select, develop, or modify clinical outcome assessments that measure outcomes important to patients.
Guidance Adds No New Paperwork
The guidance contains no new collection of information under the Paperwork Reduction Act and instead refers to previously approved OMB collections, including control numbers such as 0910-0078, 0910-0332, 0910-0231, 0910-0120, 0910-0844, 0910-0756, 0910-0449, 0910-0001, 0910-0338, 0910-0014, 0910-0130, 0910-0303, and 0910-0429. That means the guidance itself does not create new reporting requirements for regulated parties.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-20152, Notice of OFAC Sanctions Actions
The U.S. Treasury’s OFAC just blocked the property of two people from Colombia linked to illegal drug activities. From October 24, 2025, Americans can’t do business with them, freezing their assets under U.S. law. This move aims to cut off money and resources fueling the global drug trade.
Next: 2025-20155, Lightweight Thermal Paper From the People's Republic of China: Final Results of the Expedited Third Sunset Review of the Countervailing Duty Order
The U.S. Department of Commerce decided to keep extra taxes on lightweight thermal paper imported from China because stopping them could let unfair government help continue. This affects Chinese exporters and U.S. companies like Domtar that make similar paper here. These duties stay in place starting November 18, 2025, helping protect American businesses from unfair competition.